Ecdysterone and MK-2866 Interaction

Avoid
Mechanism-based 64% confidence

Ecdysterone and MK-2866 have a potentially harmful interaction with 64% confidence. Both Ecdysterone and MK-2866 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Both compounds affect the gonads and liver and heart, so monitoring these systems is recommended.

Compound Profiles

Ecdysterone

Phytoecdysteroid | Natural Anabolic & Performance Enhancer

Ecdysterone's anabolic mechanism is fundamentally distinct from that of anabolic-androgenic steroids. Rather than binding to the androgen receptor, ecdysterone exerts its effects primarily through estrogen receptor beta (ERbeta) signaling.

Half-life: ~4-9 hours Typical dose: 500-1000 mg/day (oral) or 50-100 mg/day (injectable) anabolic
estrogen receptormtorngf androgenichepatotoxichpta suppressivelipid disrupting
View full profile

MK-2866

Selective Androgen Receptor Modulator | Muscle Wasting Research

MK-2866 binds to the androgen receptor (AR) with high affinity and selectivity, functioning as a partial agonist in muscle and bone tissue. Upon binding, the MK-2866-AR complex undergoes a conformational change that promotes nuclear translocation and interaction with androgen response elements (AREs) on DNA, activating transcription of genes involved in protein synthesis, nitrogen retention, and myogenic differentiation.

Half-life: ~24 hours Typical dose: 10-25 mg/day oral sarm, anabolic
androgen receptormtormyostatin androgeniccarcinogenic riskhepatotoxichpta suppressive
View full profile

Combined Organ Load

Gonads
elevated
Liver
elevated
Heart
moderate

Shared Safety Flags

2x 2 androgenic compounds (Ecdysterone, MK-2866). Additive androgenic load — increased risk of hair loss, acne, prostate effects.
2x 2 hepatotoxic compounds (Ecdysterone, MK-2866). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.
2x 2 HPTA-suppressive compounds (Ecdysterone, MK-2866). Deep hormonal shutdown expected — plan extended PCT.
2x 2 compounds disrupt lipids (Ecdysterone, MK-2866). Get lipid panel mid-cycle — consider adding lipid support.

Frequently Asked Questions

Can I take Ecdysterone with MK-2866?

Combining Ecdysterone with MK-2866 is not recommended. Both Ecdysterone and MK-2866 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is Ecdysterone and MK-2866 safe together?

This combination carries significant risk. Both Ecdysterone and MK-2866 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between Ecdysterone and MK-2866?

Both Ecdysterone and MK-2866 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 64% confidence and is inferred from pharmacological mechanism analysis.

How should I time Ecdysterone and MK-2866?

Ecdysterone has a half-life of ~4-9 hours and MK-2866 has a half-life of ~24 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: Ecdysterone vs MK-2866

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.